Patent · US Active

Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitors

US9562076B2 · kind B2 · utility

2Cited by

5References

41Claims

0Family size

Assignee

RUPRECHT-KARLS-UNIVERSITÄT-HEIDELBERG (Rektorat) · DE

Inventors

Walter Mier · Bensheim, DE
Stephan Urban · Neustadt, DE

Key dates

Filing date	Jan 26, 2009
Grant date	Feb 7, 2017
Priority date	—
Expiry date	Jan 30, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2730/10134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.